GlassScriptPhysician profile
Mary Baiyeri
NPI 1265442040
$1,160.01
in general payments reported to CMS, 2019-2025
18 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $74.59 · 2022: $44.74 · 2023: $131 · 2024: $150 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $308.92 | 2019-2020 | |
| Ucb, INC. | $221.50 | 2019-2024 | Fintepla, Briviact |
| Neurelis, INC. | $148.87 | 2024-2025 | Valtoco |
| Tris Pharma INC | $110.94 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $66.99 | 2024 | Zonisade |
| Aquestive Therapeutics, INC. | $41.45 | 2019 | |
| Eisai INC. | $32.84 | 2019 | |
| Supernus Pharmaceuticals, INC. | $28.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.26 | 2025 | Ajovy |
| Travere Therapeutics, INC. | $23.08 | 2019 | |
| Neos Therapeutics, LP | $22.37 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.64 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.71 | 2019 | |
| Ascendis Pharma Endocrinology INC | $17.49 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $16.04 | 2019 | |
| Ptc Therapeutics, INC. | $15.03 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Baiyeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.